University of Kentucky Alzheimer's Disease Research Center

肯塔基大学阿尔茨海默病研究中心

• 批准号: 10459464
• 负责人: LINDA J VAN ELDIK
• 金额: $ 293.7万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10459464
• 关键词: Address; African American; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; Area; Autopsy; Awareness; Basic Science; Biological; Biological Markers; Biometry; Brain; Caring; Cessation of life; Clinical; Clinical Research; Clinical Trials; Cognitive; Cognitive aging; Collaborations; Collection; Communities; Community Outreach; Dementia; Development; Disease; Education; Education and Outreach; Elderly; Ensure; Environment; Etiology; Family; Goals; Health Personnel; Heterogeneity; Impaired cognition; Impairment; Individual; Infrastructure; Kentucky; Knowledge; Longitudinal cohort; Mission; NCI Scholars Program; Neurodegenerative Disorders; Outcome; Pathogenicity; Pathology; Recommendation; Research; Research Personnel; Research Project Grants; Resources; Risk; Training; Translating; Translational Research; United States; United States National Institutes of Health; Universities; aging brain; beneficiary; central database; clinical practice; cognitive development; cohesion; cohort; collaborative environment; community partnership; comorbidity; data management; driving force; education research; experience; innovation; neuropathology; next generation; normal aging; novel therapeutics; outreach; pre-clinical; programs; recruit; research study; statistics; success; volunteer

Project Summary/Abstract: Overall The University of Kentucky Alzheimer’s Disease Research Center (UK-ADRC) is an experienced and collaborative center that has facilitated pioneering research in AD and related dementias (ADRD) since its inception in 1985. Our principal mission is to serve as the focal point for all AD-related activities at UK and this region of the United States, by providing an environment and core resources that catalyze innovative research, outreach, education, and clinical programs. Our signature resources include: 1) a cognitively normal group of ~500 subjects followed longitudinally, together with ~300 additional subjects who transitioned to MCI or dementia, and all committed to brain autopsy upon death; 2) a strong autopsy program with clinical- neuropathological correlations and short postmortem interval research material; 3) a maturing program studying the early preclinical biological emergence of mixed pathologies and how they contribute to late life dementia states, with an increasing focus on antemortem biomarker collection; 4) an integrated centralized database and innovative biostatistical expertise to characterize clinical and biological transitions; 5) a successful and close partnership with the African-American community and increased participation of underrepresented individuals in our longitudinal cohort and ADRC-affiliated research studies and clinical trials; and 6) a rich, interdisciplinary training environment that provides multi-faceted educational opportunities for researchers, healthcare providers, and our community partners. The overarching theme of the UK-ADRC is: Transitions from Normal to Late-Life Multi-Etiology Dementia. Our well-characterized, longitudinal cohort and historically strong neuropathology program focused on normal aging, preclinical disease states and early cognitive transitions have been central to our success in defining early pathogenic mechanisms underlying the transitions from normal cognitive aging to impairment. In addition, these efforts have been a driving force in our recognition of the heterogeneity and multiple pathologies that characterize late-life dementia. The UK-ADRC will continue to leverage our strengths to enhance our impact and “Centerness” by our focus on this overarching theme, and the pursuit of four overall specific aims. Aim 1. Facilitate and enhance basic, translational and clinical research in AD and related dementias. Aim 2. Provide the necessary resources and interactive environment to support and create new opportunities for innovative research. Aim 3. Maintain and grow educational opportunities and community partnerships to promote awareness, increase participation in research, and provide an innovative and interdisciplinary training environment. Aim 4. Contribute to the national efforts and collaborative activities with other centers, programs and groups to advance AD/ADRD research, education, and care.

项目概要/摘要：总体 肯塔基州大学阿尔茨海默病研究中心（UK-ADRC）是一个经验丰富， 合作中心，促进了AD和相关痴呆症（ADRD）的开拓性研究，因为它的 成立于1985年。我们的主要使命是作为所有广告相关活动的协调中心在英国和这个 该地区的美国，通过提供环境和核心资源，催化创新研究， 外展、教育和临床项目。我们的签名资源包括：1）一组认知正常的 约500例受试者接受纵向随访，另外约300例受试者转为MCI或 痴呆症，所有致力于脑尸检后死亡; 2）一个强大的尸检计划与临床- 神经病理学相关性和短的死后间隔研究材料; 3）成熟的程序 研究混合病理的早期临床前生物学出现以及它们如何影响晚年生活 痴呆状态，越来越多地关注死前生物标志物的收集; 4）一个综合的集中的 数据库和创新的生物统计专业知识，以表征临床和生物学转变; 5）a 与非裔美国人社区建立成功和密切的伙伴关系， 在我们的纵向队列和ADRC附属研究和临床试验中代表性不足的个体; 6）丰富的跨学科培训环境，为学生提供多方面的教育机会， 研究人员、医疗保健提供者和我们的社区合作伙伴。联合王国-亚洲发展与和解委员会的首要主题是： 从正常到晚年多病因痴呆症的转变。我们特征鲜明的纵向队列 和历史上强大的神经病理学计划专注于正常衰老，临床前疾病状态和早期 认知转变是我们成功定义早期致病机制的核心， 从正常认知老化到认知障碍的转变。此外，这些努力也是我们 认识到老年痴呆症的异质性和多种病理特征。UK-ADRC 我们将继续利用我们的优势，加强我们的影响力和“中心地位”， 总体目标，以及四个具体目标的实现。 目标1。促进和加强AD和相关痴呆症的基础、转化和临床研究。 目标2.提供必要的资源和互动环境，以支持和创造新的机会 进行创新研究。 目标3.保持和增加教育机会和社区伙伴关系，以提高认识， 增加参与研究，并提供创新和跨学科的培训环境。 目标4。与其他中心、方案和团体一起为国家努力和合作活动做出贡献， 推进AD/ADRD研究、教育和护理。